Antimicrobial resistance (AMR) presents a global health crisis, as every day we encounter more infections that cannot be cured with existing antimicrobials. At the same time, the majority of major drug companies have been scaling back or cutting antibiotic research due to development challenges
According to the Centers for Disease Control and Prevention’s (CDC) Flu View, seasonal influenza activity in the U.S. is currently high. Thousands have already been hospitalized this season from influenza-associated illnesses and flu activity has continued to increase.
About 80 percent of all antibiotics used in the U.S. are used in the animal health and agriculture sectors. This portion contributes significantly to antimicrobial resistance (AMR), as antibiotic dosing regimens tend to be less controlled in agriculture compared to human medicine. AMR is one of our world’s most pressing healthcare challenges and the misuse of antibiotics causes AMR to occur more rapidly.
Throughout 2019, the transformation of diagnostic technology has been centered around machine learning, maximizing patient value, and the needs of those with chronic ailments and diseases. As technology advances, so does the ability to diagnose and treat, whether in the ICU or over the phone.